CNAT - コナタス・ファ―マシュ―ティカルズ (Conatus Pharmaceuticals Inc.)


   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Is Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers?  2019/11/03 13:22:39 ACI Information Group
In 2005 Steven Mento was appointed CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). First, this article will compare…
   Caspase 3 Market Comprehensive Study by Leading Players- Aptose Biosciences, BeyondSpring Pharmaceuticals, Conatus Pharmaceuticals  2019/11/02 09:57:00 MarketWatch
Nov 02, 2019 (HTF Market Intelligence via COMTEX) -- An extensive analysis of the Global Caspase 3 market strategy of the leading companies in the precision…
   Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know  2019/08/19 13:00:08 Zacks Investment Research
Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies  2019/08/07 10:00:00 Zacks Investment Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.